Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19

Overview

Journal Tanaffos

Specialty Pulmonary Medicine

Date 2020 Dec 2

PMID 33262793

Citations 6

Authors

Mitra Rezaei

Abdolreza Babamahmoodi

Majid Marjani

Affiliations

Soon will be listed here.

Citing Articles

The Relationship between the Clinical Course of SARS-CoV-2 Infections and Expression of Bruton's Tyrosine Kinase.

Rezaei M, Babamahmoodi A, Mirahmadi A, Bineshfar N, Mahmoudi S, Ghadimi S Infect Disord Drug Targets. 2024; 25(1):e270624231361.

PMID: 38939988 DOI: 10.2174/0118715265301312240529044923.

Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.

Wang L, Wang L Immunotargets Ther. 2022; 11:23-35.

PMID: 35611161 PMC: 9124488. DOI: 10.2147/ITT.S360151.

Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines.

Tuli H, Sak K, Aggarwal P, Iqubal A, Upadhaya S, Kaur J Front Cell Infect Microbiol. 2021; 11:763687.

PMID: 34970505 PMC: 8712944. DOI: 10.3389/fcimb.2021.763687.

BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.

Stack M, Sacco K, Castagnoli R, Livinski A, Notarangelo L, Lionakis M Clin Immunol. 2021; 230:108816.

PMID: 34352390 PMC: 8327577. DOI: 10.1016/j.clim.2021.108816.

Gene expression analysis of MCF7 cell lines of breast cancer treated with herbal extract of revealed association with viral diseases.

Guven E Gene Rep. 2021; 23:101169.

PMID: 33907720 PMC: 8062415. DOI: 10.1016/j.genrep.2021.101169.

References

Galimberti S, Baldini C, Barate C, Ricci F, Balducci S, Grassi S . The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacol Res. 2020; 157:104866. PMC: 7202852. DOI: 10.1016/j.phrs.2020.104866. View

Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E . Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020; 31(5):565-569. PMC: 7264678. DOI: 10.1111/pai.13263. View

Liang C, Tian D, Ren X, Ding S, Jia M, Xin M . The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem. 2018; 151:315-326. DOI: 10.1016/j.ejmech.2018.03.062. View

Berlin D, Gulick R, Martinez F . Severe Covid-19. N Engl J Med. 2020; 383(25):2451-2460. DOI: 10.1056/NEJMcp2009575. View

Singh S, Dammeijer F, Hendriks R . Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018; 17(1):57. PMC: 5817726. DOI: 10.1186/s12943-018-0779-z. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Sanders J, Monogue M, Jodlowski T, Cutrell J . Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 323(18):1824-1836. DOI: 10.1001/jama.2020.6019. View

Tillman B, Pauff J, Satyanarayana G, Talbott M, Warner J . Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2017; 100(4):325-334. DOI: 10.1111/ejh.13020. View

Treon S, Castillo J, Skarbnik A, Soumerai J, Ghobrial I, Guerrera M . The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020; 135(21):1912-1915. PMC: 7243149. DOI: 10.1182/blood.2020006288. View

10.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J . Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92(7):814-818. PMC: 7262125. DOI: 10.1002/jmv.25801. View

11.

Gandhi R, Lynch J, Del Rio C . Mild or Moderate Covid-19. N Engl J Med. 2020; 383(18):1757-1766. DOI: 10.1056/NEJMcp2009249. View

12.

Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J . Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol. 2020; 190(2):e73-e76. PMC: 7276870. DOI: 10.1111/bjh.16863. View

13.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I . Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020; 2(7):e393-e400. PMC: 7259909. DOI: 10.1016/S2665-9913(20)30164-8. View

14.

Felsenstein S, Herbert J, McNamara P, Hedrich C . COVID-19: Immunology and treatment options. Clin Immunol. 2020; 215:108448. PMC: 7185015. DOI: 10.1016/j.clim.2020.108448. View

15.

Weber A, Bittner Z, Liu X, Dang T, Radsak M, Brunner C . Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol. 2017; 8:1454. PMC: 5682317. DOI: 10.3389/fimmu.2017.01454. View

16.

Florence J, Krupa A, Booshehri L, Davis S, Matthay M, Kurdowska A . Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018; 315(1):L52-L58. PMC: 6087894. DOI: 10.1152/ajplung.00047.2018. View

17.

Chong E, Roeker L, Shadman M, Davids M, Schuster S, Mato A . BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clin Cancer Res. 2020; 26(14):3514-3516. PMC: 7367762. DOI: 10.1158/1078-0432.CCR-20-1427. View

18.

Roschewski M, Lionakis M, Sharman J, Roswarski J, Goy A, Monticelli M . Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020; 5(48). PMC: 7274761. DOI: 10.1126/sciimmunol.abd0110. View